37.24
-1.65(-4.24%)
Currency In USD
Address
200 Cambridge Park Drive
Waltham, MA 02140
United States of America
Phone
617 945 5576
Website
Sector
Healthcare
Industry
Biotechnology
Employees
205
First IPO Date
March 29, 2018
| Name | Title | Pay | Year Born |
| Andrew R. Robbins | President, Chief Executive Officer & Director | 1.18M | 1976 |
| Cole Pinnow | Chief Commercial Officer | 443,154 | 1975 |
| John L. Green | Chief Financial Officer & Principal Accounting Officer | 729,237 | 1980 |
| John Edward Robinson | Chief Scientific Officer | 788,901 | 1974 |
| Jessica Sachs | Chief Medical Officer | 814,184 | 1975 |
| Brad Barnett | Chief Technology Officer | 0 | N/A |
| Dana R. Martin | Senior VP of Medical Affairs & Chief Patient Officer | 0 | N/A |
| Evan D. Kearns | Chief Legal Officer & Corporate Secretary | 0 | 1979 |
| Christi Waarich | Senior Director of Investor Relations | 0 | N/A |
| Erin Schellhammer | Chief People Officer | 0 | N/A |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.